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Abstract
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries. It has recently been shown
that the homogeneity of the chromatin landscape between CLL cells contrasts with the important observed genetic
heterogeneity of the disease. To gain further insight into the consequences of disease evolution on the epigenome’s
plasticity, we monitored changes in chromatin structure occurring in vivo in CLL cells from patients receiving
continuous Ibrutinib treatment. Ibrutinib, an oral inhibitor of the Bruton’s tyrosine kinase (BTK) has proved to be
remarkably efﬁcient against treatment naïve (TN), heavily pre-treated and high-risk chronic lymphocytic leukaemia
(CLL), with limited adverse events. We established that the chromatin landscape is signiﬁcantly and globally affected in
response to Ibrutinib. However, we observed that prior to treatment, CLL cells show qualitative and quantitative
variations in chromatin structure correlated with both EZH2 protein level and cellular response to external stimuli.
Then, under prolonged exposure to Ibrutinib, a loss of the two marks associated with lysine 27 (acetylation and
trimethylation) was observed. Altogether, these data indicate that the epigenome of CLL cells from the peripheral
blood change dynamically in response to stimuli and suggest that these cells might adapt to the Ibrutinib “hit” in a
process leading toward a possible reduced sensitivity to treatment.
Introduction
Chronic lymphocytic leukaemia (CLL) originates from
clonal proliferating B-cells with patients mainly present-
ing with lymphadenopathy, splenomegaly, and lympho-
cytosis1. A combination of ﬂudarabine, cyclophosphamide
and rituximab (FCR) represents the standard therapy2.
However, a majority of patients relapse with most of them
eventually succumbing to CLL. Encouraging results of
several forerunner clinical trials that target the activity of
PI3Kδ, BTK or SYK, highlight the therapeutic potential of
inhibiting BCR signalling3,4. Ibrutinib (PCI-32765), a
speciﬁc and irreversible inhibitor of Bruton’s Tyrosine
Kinase (BTK), is a small molecule orally administered,
providing a selective and irreversible inhibition of BTK. In
extensive studies, Ibrutinib has shown extremely pro-
mising results in front-line treatment as well as in
relapsed/refractory (RR) CLLs5,6 and is now tested in
combination with other molecules7. However, cases of
drug resistance have emerged8,9.
In recent years, a large body of work has highlighted the
complexity of the regulatory mechanisms controlling gene
expression by external environmental stimuli and signal-
ling pathways for which chromatin plays a central role.
The eukaryotic genomes are partitioned into functionally
autonomous clusters in which gene expression is either
positively or negatively controlled. In active clusters,
promoters are highly enriched for the histone lysine 4
trimethylation mark (H3K4me3), whereas activated
enhancers display enrichment of histone H3 lysine 4
mono-methylation and di-methylation (H3K4me1/2) and
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lysine 27 acetylation (H3K27ac). The equilibrium between
open and repressed chromatin is dynamic and can change
transiently or permanently in response to various endo-
genous or exogenous stimuli. These processes are con-
trolled by several classes of epigenetic factors. One such
class of key epigenetic regulators are the polycomb group
(PcG) proteins, which are a family of transcriptional
repressors, primarily known in maintaining cell identity,
but also implicated in the control of cellular proliferation
and neoplastic development10–12. A recent study has
shown that the lack of transcription triggers deposition of
H3K27me3, the repressive mark mediated by the
polycomb-repressive complex 2 (PRC2)13. The core PRC2
complex comprises of four components, its enzymatic
subunit with methyltransferase activity EZH1 or EZH2,
SUZ12, EED and RbAp46/48. Furthermore, bivalent
promoters, which harbour both active and silent marks
(H3K4me3, H3K27me3), are usually CpG rich14. They
have been mainly identiﬁed in stem cells, but can persist
during differentiation as seen in T and B cells15.
EZH2 expression is correlated with proliferation to
oppose cell division-mediated dilution of H3K27me316. In
B cells, EZH2 is highly expressed in lymphoid progenitors
and is necessary for early lymphopoiesis17. EZH2 declines
in mature resting B cells but is transiently reactivated in
the germinal centre where dividing Ki67+ centroblasts
are associated with its expression18,19. EZH2 is required
for the formation and function of the germinal centre,
where it participates to the establishment of bivalency at
key regulatory promoters to transiently block
differentiation15.
A recent study proposed an extensive epigenomic
characterisation of CLL cells, which indicated that if DNA
methylation or chromatin accessibility shows patterns
characteristic of the cellular origin of these cells, active
chromatin marks like H3K27ac follow other more com-
plex dynamics20. To further assess the correlation
between chromatin organisation and the evolution of the
disease, we analysed the plasticity of the chromatin
landscape of CLL cells from patients treated with
Ibrutinib.
Our analysis revealed that the CLL cell populations in
the peripheral blood was heterogeneous, including cells
with various proportions of epigenomic traits character-
istic of activated B cells. Moreover, the initial chromatin
remodelling in response to Ibrutinib was dependent upon
these initial traits but was converging toward a similar
organisation after few months. Prolonged exposure to
Ibrutinib, inducing forced maintenance of cells in G0
phase, was associated with a complete loss of H3K27 post-
translational modiﬁcations including the polycomb-
dependent repressive mark. This work suggests that
CLL cells lose some epigenetic constraints in response to
treatment.
Results
Prolonged Ibrutinib treatment correlates with loss of
histone H3K27 marks
The IcICLLe trial is a feasibility study investigating the
mechanism of action of Ibrutinib. Patients received con-
tinuous oral therapy with Ibrutinib (420 mg OD) and CLL
cells were collected from the peripheral blood before and
at regular time points during treatment (Supplementary
Table 1). The percentage of Ki67-positive cells in the
blood increased in the ﬁrst 24 h after Ibrutinib treatment
initiation but then dropped rapidly to completely dis-
appear after 14 days in all patients (Fig. 1a). At the same
time, an important and transient increase in CLL cell
count, characteristic of Ibrutinib-dependent lymphocy-
tosis, occurred within the ﬁrst hours after the start of the
treatment and fall back signiﬁcantly to its initial level from
14 days and 2 months for treatment naïve (TN) and RR
patients, respectively (Fig. 1b). This result is consistent
with previously described Ibrutinib-dependent rapid
reduction of lymphadenopathy accompanied by transient
lymphocytosis in CLL21.
EZH2 is a marker of proliferation transiently reactivated
in proliferation centre in normal B cells16,18,19. Therefore,
we hypothesised that EZH2 protein level could serve as a
suitable marker of lymphocytosis. EZH2 expression was
not correlated with the evolution of B cell count in the PB,
but either transiently increased in CLL after 14–28 days
on Ibrutinib or present at a moderate level before treat-
ment and going progressively down with prolonged
exposure to the drug (Fig. 2a). Then, ChIP-seq experi-
ments were performed for EZH2, H3K4me3 and
H3K27me3 at 0, 7 and 56 days after the ﬁrst treatment
administration for N1 and N2 patients and H3K27ac for
patients N3 and R3 (Fig. 2, Supplementary Fig. S1).
Within H3K27me3-low regions, H3K27ac and/or
H3K4me3 peaks corresponding to clusters of transcribing
genes were observed as seen for the CXCR4 locus and two
genomic regions randomly chosen and centred on the
FOXP1 and BCL2 genes, respectively (Fig. 2b, Supple-
mentary Fig. S1). In patient N2, in response to Ibrutinib
and correlated with lymphocytosis, we observed, at 7 days,
a transient and genome-wide increase in EZH2 recruit-
ment and H3K27me3 at “active” regions (Fig. 2b, Sup-
plementary Fig. S1B, D). This transient increase in
H3K27me3 was also detected by conventional ChIP in six
randomly chosen patients from the trial as shown for
patient N4 (Fig. 2c). In contrast, in patient N1, EZH2/
H3K27me3 enrichment within “active” regions was seen
at the time of treatment initiation (Fig. 2b, Supplementary
Fig. S1A and C). For this patient, the enhanced level of
H3K27me3 correlating with EZH2 recruitment was sub-
tler than when observed post treatment.
In addition, independently of the initial EZH2 protein
level, prolonged and continuous exposure to Ibrutinib-
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induced loss of EZH2 protein and H3K27me3 (Fig. 2a, d,
Supplementary Fig. S2B). Similarly, H3K27ac, which
antagonises H3K27me3, disappeared from 56 days after
treatment initiation in contrast to the H3K4me3 mark
which was relatively stable upon prolonged drug exposure
(Fig. 2b, d, Supplementary Fig. S2A). In conclusion, these
data show that long-term Ibrutinib treatment induced a
severe reduction of both histone H3 lysine 27 acetylation
and methylation together with EZH2 protein dis-
appearance in CLL cells.
In depth analysis of EZH2 recruitment to active cis-
regulatory elements
To study EZH2 recruitment and H3K27me3 deposition
in “active” chromatin domain in more detail, we separated
the cis-regulatory elements positive for EZH2, H3K4me3
and/or H3K27me3 into seven subgroups before treatment
and after 7 days on Ibrutinib. This analysis was performed
with the data obtained from patient N1 (Fig. 3a, b) as the
remarkable genome-wide increase of H3K27me3 in
patient N2 at 7 days was preventing an accurate quanti-
ﬁcation of positive peaks vs. background.
When EZH2 was targeting regions enriched for
H3K27me3, we observed only 2.5% increase in EZH2
bound cis-elements between 0 and 7 days (subgroups 1
and 2) (Fig. 3a, b). In contrast, if EZH2-targeted regions
were negative for H3K27me3, EZH2 occupancy decreased
by 38% (EZH2-only, subgroup 4) and 50% (EZH2 and
H3K4me3, subgroup 3) after 7 days on Ibrutinib. An
opposite evolution (30% increase) was observed for
Fig. 1 Ibrutinib treatment induces lymphocytosis in CLL cells. a Evolution of CLL cells count and (B) Ki67+ cells for the 16 patients included in
the study comparing treatment-naïve (TN) and relapsed-refractory (RR) patients during (a) the ﬁrst 120 days or (b) up to 9 months on Ibrutinib.
Peripheral CLL cell counts from peripheral blood are expressed as a ratio vs. cell count the day of the ﬁrst Ibrutinib ingestion. Paired Student’s t-test
has been performed comparing cell count at variable time points compared to T0, *t-value < 0.05, **t-value < 0.01 and ***t-value < 0.001. Student’s t-
test has also been performed comparing TN to RR for each time point, +t-value < 0.05
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H3K4me3-only regions (subgroup 7) (Fig. 3a, b). More-
over, EZH2 was redeployed from H3K4me3 high pro-
moters to H3K27me3-enriched region as highlighted with
EZH2 barcodes (subgroups 2 and 4) (Fig. 3b). Altogether,
these data indicated that the mechanism of EZH2 dis-
sociation from active clusters described above was par-
tially due to a redeployment of EZH2 to repressed
chromatin in addition to a global decrease in EZH2 pro-
tein associated with chromatin.
Next, we analysed the intersection between our peak
libraries and merged transcription factors ChIP-seq data
obtained from a publicly available database (ReMap). This
analysis, referred to as ReMap and Epigenetic Marks
Intersection (REMI), calculates the number of cis-
regulatory elements enriched for a speciﬁc histone mark
and containing a validated consensus sequence corre-
sponding to a speciﬁc transcription factor. It allowed us to
generate “signatures” associated with determined peak
populations and to assess the relative variation of these
signatures when comparing one peak population to
another (Supplementary Figs. S3 and 4). For example, we
established that non-promoter elements were enriched
for transcription factors expressed in B cells and impor-
tant for B cell function including SMAD1, IKZF1, BATF
or BCL11A22–25, and promoter elements enriched for
proteins like KDM5A/B, IRF3, TAF3 and GTF2B (Sup-
plementary Figs. S3 and 4).
Using REMI analysis, we observed that before treat-
ment, H3K4me3+/EZH2+ cis-elements were enriched for
factors detected at promoters and depleted from speciﬁc
categories of peaks enriched for SMAD2/3/4, SOX2 and
EZH2/SUZ12 (Supplementary Fig. S5A–D). It was at ﬁrst
surprising to ﬁnd EZH2-bound regions depleted from the
EZH2/SUZ12 validated sequences assembled in the
ReMap database. However, when analysing the repartition
of EZH2-assembled sequences from ReMap compared to
the seven subgroups identiﬁed in Fig. 3, we determined
that these sequences were mainly associated with bivalent
promoters (Supplementary Fig. S5B). Moreover, these
sequences were also the most represented at CpG islands
when compared to promoter regions (Supplementary Fig.
S6B). We concluded that our ChIP-seq experiments were
showing an under-representation of EZH2 in regions
where chromatin was “permanently” repressed
(H3K27me3 was stable with time on Ibrutinib). These
regions are enriched for the EZH2-validated sequences
from ReMap (e.g. ChIP-seq performed on stem cells or
partially dedifferentiated cell lines).
SMAD2, 3 and 4 were also found depleted from the
H3K4me3+/EZH2+ fraction. Most of SMADs
Fig. 2 Polycomb-dependent silencing follows Ibrutinib-induced lymphocytosis. a Immunoblotting showing the evolution of EZH2 protein level
(patients R4 and N6) for up to 1 year on Ibrutinib. b Summary of the ChIP-seq data focussing on the CXCR4 locus obtained before treatment and after
7 and 56 days on Ibrutinib. ChIP-seq has been performed for H3K4me3, H3K27me3 and EZH2 (patients N1 and N2) and H3K27ac (patients R3 and N3).
c Time course of the evolution of the H3K27me3 PTM in selected cis-elements for the ﬁrst 56 days on Ibrutinib (N4). d Immunoblotting showing the
evolution of H3K27ac, H3K27me3 and H3K4me3 marks for up to 6 months on Ibrutinib (N5)
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downstream genes were associated with signal transduc-
tion and response to stimuli and included FOXO1 and
FOXO3, two transcription factors that mediate quies-
cence26,27 (Supplementary Figs. S5A, D, E, S6A, Supple-
mentary Table 2.1). Moreover, only two out of six samples
of CLL cells showed a signiﬁcant CXCR4 and RAC1
increased mRNA level in response to both TGFß (SMAD-
activating signal) and WNT-signalling activation in vitro
(Supplementary Fig. S5F) as described from previous
reports28. These data suggest that CLL cells might be
sensitive to TGFß and WNT signalling during very spe-
ciﬁc window(s) of their life cycle. In conclusion, our data
suggest that some H3K4me3+-regulatory elements might
be actively protected from this observed genome-wide
PRC2 recruitment.
Coordinated changes in H3K4me3 peak repartition and
intensity at selected cis-elements in Ibrutinib-treated CLL
cells
To assess the evolution of the repartition of the
H3K4me3+ peaks between patients and in reponse to
Ibrutinib, we generated scores for each set of data com-
pared to the average scores obtained for the ﬁve samples
analysed before treatment and used patient N1 before
treatment as a reference proﬁle as described (Supple-
mentary Fig. S7, Supplementary Table 5). In this reference
sample, EZH2 recruitment to active cis-elements corre-
lated with increased scores for transcription factors
enriched at non-promoter elements and slightly decreased
ones for factors like EZH2 and SUZ12 compared to the
average scores (Fig. 4a, Supplementary Table 5).
Fig. 3 EZH2 redeployment from silenced to open chromatin. a Number of cis-regulatory elements associated with EZH2, H3K4me3 and/or
H3K27me3 before and after 7 days on Ibrutinib according to the ChIP-seq analysis for N1. b Heat map showing the repartition of the seven subsets
presented in a. The barcodes on the right part of the ﬁgure represent EZH2 ChIP-seq data at 7 and 0 days
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Interestingly, comparable proﬁles were observed for CLL
cells from patients treated for a week or less with Ibrutinib
(blue circles) for which the scores for transcription factors
enriched at non-promoter elements are similar or even
higher (Fig. 4b–f). In contrast, after 2 months treatment
(orange squares), the number of H3K4me3 peaks at non-
promoter and EZH2/SUZ12-associated cis-elements were
signiﬁcantly reduced (Fig. 4b–f). These differences were
more accentuated in TN compared to RR patients (Fig.
4f), the latter category having a prolonged phase of lym-
phocytosis compared to the former (Fig. 1b).
Furthermore, we identiﬁed 253 genes closest to
H3K4me3 peaks found in all ﬁve blue proﬁles but in none
of the orange ones and determined that they were coding
for proteins mainly involved in cell proliferation, response
to external stimulus and metabolic process (Supplemen-
tary Table 5) suggesting that these peaks were char-
actersitic of activated cells coming from the proliferation
centre of the lymph node (Fig. 4b–f). Interestingly, this
family of peaks could be found before treatment in N1
and N3 but not in N2, R1 and R2 (Fig. 4b–f) suggesting
episodes of lymphocytosis prior treatment.
Having analysed H3K4me3 peak repartition evolution,
we then focussed on the evolution of their intensity with
time on Ibrutinib. H3K4me3 global intensity stayed stable
with time during treatment (Fig. 2d), but taken
individually, H3K4me3 peak intensity showed variation at
1 and 56 days on Ibrutinib compared to before treatment
(Fig. 5a, b). To determine if these variations were purely
stochastic or were co-ordinately affecting speciﬁc families
of peaks, we compared the composition of the bottom
(most decreased compared with before treatment) and top
(most increased compared with before treatment) peaks at
56 days for the promoter-associated and non-promoter-
associated H3K4me3 marks, respectively (black boxes),
with the one obtained for the total amount of H3K4me3
peaks (Fig. 5c). In agreement with changes observed for
the repartition of H3K4me3 peaks, the “top” subset was
enriched for transcription factors associated with acti-
vated B cells and B cell functions (Fig. 5a–c, Supple-
mentary Table 2.2), and the “bottom” subset enriched for
promoter regions associated with EZH2/SUZ12, which
were identiﬁed in patient N1 at bivalent promoters and
CpG islands (Fig. 5a–c, Supplementary Table 2.3). CtBP2,
which was enriched in the “bottom” subset is not
expressed in CLL but has been shown to participate in
PRC2 recruitment at active embryonic stem cells during
exit from pluripotency29, which reinforces the view that
EZH2/SUZ12 ReMap libraries were biased toward earlier
differentiation stages.
We analysed these variations in H3K4me3 peak inten-
sity for patients N1–3 and R1–2 over time (Figs. 5 and 6,
Fig. 4 Ibrutinib-dependent and Ibrutinib-independent repartition of H3K4me3 peaks. a Cis-elements enriched for the H3K4me3 mark were
screened for the presence of validated binding sites for transcription factors and co-regulators (ReMap database). For each protein of the database,
data were expressed as a score calculated using the highlighted equation allowing comparison between N1 and an average of N1–3, R1–2 samples
before treatment. Scatter diagrams representing a comparison between REMI’s scores for samples (b) N1, (c) N2, (d) N3, (e) R1 and (f) R2 and
reference proﬁle N1 at 0 day, with time points before treatment in grey triangles, at 56 days in orange rectangles and at 1 or 7 days in blue circles.
Details of the calculated scores are presented in Supplementary Table 5
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Fig. 6 Subclasses of H3K4me3-positive cis-elements are differentially affected by Ibrutinib treatment. (a) Promoters and (b) non-promoters
repartition of the H3K4me3 peaks into the three subclasses, group A (EZH2, SUZ12 and CtBP2), group B (BCL11A, IKZF1, BATF and SMAD1) and group
C (KDM5A, IRF3, GATAD1, SNAPC1). The peaks were ranked based on the fold change in magnitude between the time points and binned into subsets
containing 1000 peaks. Each of these subsets was analysed in REMI to assess the evolution of the number of peaks associated with the factors from
each group a, b, c calculated as score (Eq. (3) in supplementary methods)
Fig. 5 H3K4me3 peak intensity changes in response to Ibrutinib. a Heat map of the H3K4me3 peaks in promoters and non-promoters after 0, 1
and 56 days on Ibrutinib (patient R2). Peaks are ranked based on fold change (FC) at 56 days vs. 0 day and separated based on FC= 1.5 (largest to
smallest). b Corresponding average peak intensities are shown for the stable, decreased and increased peak fractions. c REMI analysis-derived score
for the factors associated with the decreased promoters (left) and increased non-promoter (right) fractions at 56 days (Eq. (2) in supplementary
methods). Data are ranked from the most enriched to the most depleted
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Supplementary Fig. S8 and 9). First, the heatmap proﬁles
suggest an important heterogeneity in the amount and
intensity of peak changes in response to treatment (Fig.
5a, Supplementary Fig. S8). However, when the ranked
peaks (based on fold change) were binned into 1000 peak
subsets and the composition of each subset analysed in
REMI compared to the composition observed for all the
peaks together, we identiﬁed four categories of cis-
elements behaving co-ordinately. Groups A and B repre-
sent the family of peaks enriched in the “bottom” subset
(EZH2/SUZ12/CtBP2-containing sequences, bivalent cis-
elements) or in the “top” subset (IKZF1, SMAD1, BATF
and BCL11A-containing sequences, lineage-speciﬁc) for
patient R2, respectively (Fig. 5c, Supplementary Fig. S4).
Group C (GATAD1, KDM5A, IRF3 and SNAPC1) and D
(SMAD2–4) contains transcriptions factors enriched and
depleted in the H3K4me3+/EZH2+ subset, respectively
(Supplementary Fig. S5A). The peaks from group D were
evenly distributed suggesting that these regions were not
sensitive to Ibrutinib treatment (Supplementary Fig. S9A).
In contrast, group A was found correlated with peaks for
which H3K4me3 enrichment was decreasing in promoter
and non-promoter regions after 2 months on Ibrutinib
(Fig. 6a, b). These regions were mainly bivalent regions
(Supplementary Fig. S9B). This effect was observed as
early as 1 day for patient R2 or 7 days for patient
N3 suggesting variable dynamics in response to treatment
but with a common outcome (Fig. 6a, b). Group C was
globally depleted from the regions enriched for group A
suggesting that these peaks were protected from deme-
thylation indicating that EZH2-recruitment was not fol-
lowed by epigenetic silencing (Fig. 6a). In group B,
patients N1 and N2 showed opposite distribution at
7 days (Fig. 6b) as an indication that H3K4me3 intensity
was increasing at enhancer elements targeted by EZH2
(Fig. 2b, Supplementary Fig. S1). For this group, the peak
repartition was the same for patients N2, N3, R1 and R2 at
early time points suggesting that EZH2-transient
recruitment occurred in response to Ibrutinib in four
out of the ﬁve studied CLL patients (Fig. 6b). Moreover,
this enrichment for “lineage speciﬁc” peaks in H3K4me3-
increased fraction was maintained at 56 days in both RR
patients but not in TNs suggesting a difference in the
kinetics of Ibrutinib response between these two cate-
gories of patients as indicated by the evolution of CLL cell
count and H3K4me3 peak repartition (Figs. 1a and 4).
RR CLL cells may have undertaken partial reprogramming
in response to FCR
To further investigate the differences between the two
RR and three TN patients, we selected the 825 RR-speciﬁc
peaks (Fig. 7a). EZH2 and SUZ12 were the only two fac-
tors enriched in this subset suggesting activation of cis-
regulatory elements silenced in CLL cells from TN
patients (Fig. 7a, Supplementary Fig. S10A-B). Accord-
ingly, these polycomb-associated regions were enriched
for genes involved in cell signalling and system develop-
ment including functions associated with other lineages
usually silenced in B cells (Supplementary Fig. S11, Sup-
plementary Table 2.4). This analysis, restricted to “pre-
sence or absence” of H3K4me3 peaks, underestimated the
differences between RR and TN patients. This is illu-
strated by the TIAM1 gene locus, where at the promoter
H3K4me3 is low but not completely absent for N1, N2
and N3 (Supplementary Fig. S12). Interestingly, these
epigenetic differences were not seen at TIAM1 mRNA
level which was low in both RR and TN patients before
treatment (data not shown).
Discussion
In CLL, clonal evolution leading to resistance to Ibru-
tinib has been described9, but the lymphocyte count sta-
bilisation after long-term exposure to the drug observed
in the majority of Ibrutinib-treated patients cannot be
explained solely by the presence of resistant clones30,31.
This absence of remission correlates with the epigenetic
changes we observed, suggesting that cancer cells can also
change phenotypically in response to treatment (Fig. 7b).
Ibrutinib treatment includes loss of both H3K27ac and
H3K27me3 marks in every patient tested. Hypomethyla-
tion is a characteristic of quiescent cells and an indicator
of enhanced plasticity32–34. These changes could partici-
pate in the mechanisms of resistance as described
previously35.
Analysing the dynamics of lymphocytosis following
Ibrutinib treatment in CLL cells reveals that the response
to Ibrutinib tends to be quicker in TN patients and
delayed in RR patients36. In this study, this delay can be
linked with a signiﬁcant number of promoters showing
bivalency in RR patients but fully silent in TN patients,
including TIAM1, which has been shown to mediate
chemoresistance to ﬂudarabine in CLL37. Maintenance of
H3K4me3 at PRC2 targets in RR patients argues for a
mechanism of partial reprogramming that takes place
during the process of relapse induced by FCR and for
which these patients have kept an epigenetic memory
which could decrease their sensitivity to Ibrutinib. Further
investigation with more CLL samples will be necessary to
conﬁrm this point.
EZH2 expression is restricted to proliferative cells in
cancer and non-transformed human cells38 and, accord-
ingly, to the proliferation centre in B cells18,19. Therefore,
transient increases in protein level as well as an enhanced
interaction with chromatin, and more speciﬁcally with
H3K4me3+ cis-elements in correlation with treatment
initiation, can be interpreted by an enrichment of CLL
cells accumulating in the blood from the lymph node.
Interestingly, a signiﬁcant level of EZH2 protein and
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EZH2–chromatin association on the day of treatment
initiation could also be seen as an indication of a drug-
independent mechanism of lymphocytosis commonly
seen in CLL. When EZH2 was measured at day 0, treat-
ment initiation was not provoking any surge in EZH2-
expressing cells to the PB suggesting temporary exhaus-
tion of these cells in the lymph node post lymphocytosis.
Moreover, H3K27me3 increase at EZH2-bound cis-ele-
ments was relatively subtle when EZH2 was associated
with chromatin at the beginning of the treatment sug-
gesting that EZH2 might be recruited in an inactivated
form. Transcription can repress PRC2 activity through its
interaction with nascent transcripts39,40 and therefore
antagonising PRC2 binding to chromatin41. Our data
suggest a possible two-step mechanism in which PRC2 is
recruited to active cis-elements preventing
promoter–enhancer interaction. At this stage, a low level
of transcription might prevent PRC2 interaction with
chromatin and H3K27 acetylation/methylation switch.
Then in response to Ibrutinib, additional repression
mechanisms may play a role in favour of a strong
repressive state and H3K27me3 deposition. A similar
mechanism has been described in Drosophila in response
to heat shock accompanied by a global chromatin 3D
reorganisation driven by polycomb42.
In addition, an in-depth analysis of the evolution of
H3K4me3 peak repartition and intensity during the ﬁrst
2 months of treatment revealed epigenomic plasticity
both Ibrutinib-dependent and Ibrutinib-independent.
First, regions targeted by EZH2 were protected from
H3K4me3 demethylation and, for non-promoter elements
targeted by B-cell-speciﬁc transcription factors, correlated
with a transient increase in H3K4me3. This may be due to
an increase in enhancer-speciﬁc noncoding RNA (eRNA)
transcription. Second, stable bivalent cis-elements
appeared to be among the regions excluded from this
transient EZH2 recruitment, which was in agreement with
a role for EZH2 in de novo H3K27 methylation and EZH1
for the maintenance of this mark43. Moreover, these
bivalent cis-elements showed a trend toward reduction of
H3K4me3 peak intensity in all patients, suggesting a
correlation between a prolonged exit from the cell cycle as
a consequence of Ibrutinib treatment and demethylation
of both H3K27me3 and H3K4me3 at silenced chromatin.
Some H3K4me3+ cis-elements were speciﬁcally pro-
tected from EZH2 recruitment and in particular regions
Fig. 7 The initial number of bivalent promoters is higher in relapsed/refractory compared to treatment naïve patients. a Methodology to
isolate H3K4me3 peaks found in both R1 and R2 but not in either of N1, N2 or N3 and REMI analysis of R1 and R2 only peaks shown as score (Eq. (2) in
supplementary methods). b Summary of the chromatin alterations induced by Ibrutinib. In response to Ibrutinib, proliferation is blocked and two
populations of cells are seen depending on the level of EZH2 protein before treatment. Polycomb-dependent silencing is associated with a transient
increase in EZH2/H3K27me3 at “active” cis-elements. The H3K27ac and H3K27me3 marks are lost in correlation with the observed global changes in
gene expression and a possible increased plasticity and enhanced proliferation potential
Holmes et al. Oncogenesis            (2019) 8:32 Page 9 of 11
Oncogenesis
potentially targeted by SMAD2–4. TGFß has been shown
to be inhibitory at almost any B-cell stage44 and may
participate in the reorganisation of the transcriptome
during the transition from the proliferative to the resting
phase. This hypothesis is reinforced by the presence of
FOXO1 and FOXO3 in the list of genes protected from
EZH2 recruitment and potentially targeted by SMAD2–4.
FOXO1 and FOXO3 control a transcriptional programme
repressing cell proliferation and promoting resistance to
stress and survival45. Moreover, the expression of these
two transcription factors is downregulated by the BCR
signalling46. Interestingly, SMAD6 and SMAD7, the two
inhibitors of TGFß signalling47,48 are also among the
genes identiﬁed within the EZH2−/SMAD2–4+ fraction,
arguing for a short window of activation of this signal as
suggested by the observed variability in CLL response to
TGFß1 in vitro. In addition, TGFß-induced quiescence
has been recently shown to mediate chemoresistance in
squamous cell carcinoma49. Altogether, these data suggest
that the passage from proliferating to quiescence in
response to Ibrutinib is controlled by polycomb and
potentially TGFß.
In conclusion, chromatin structure changes dynamically
in response to Ibrutinib in CLL cells in a two-step
mechanism leading to the loss of H3K27 marks and
correlated with the stabilisation of CLL cell count. His-
tone hypomethylation associated with prolonged exit
from the cell cycle has been connected to mechanisms of
survival and enhanced plasticity and can be seen as an
adaptive response to Ibrutinib. Further investigation will
be necessary to assess if these changes provoke a reduced
sensitivity to treatment and participate in the mechanism
of relapse.
Materials and methods
Isolation of CLL cells
Peripheral blood was collected from patients with
informed written consent (St. James’ University Hospital,
approval number 14/YH/0034). Peripheral blood mono-
nuclear cells (PMBCs) were isolated by density gradient
centrifugation using LymphoprepTM (Axis-Shield). CLL
cells were further puriﬁed using CD19+ MicroBeads
(Miltenyi Biotec). Due to the restricted cell number for
each collected time points, puriﬁed cells were used for
immunoblotting, gene expression or chromatin immu-
noprecipitation as described below.
Immunoblot analysis
Cells were lysed in a buffer containing 50mM Tris–HCl
(pH 6.8), 1.5% SDS and 1x protease inhibitor cocktail
(ThermoFischer Scientiﬁc). Protein concentration was
determined using Pierce BCA™ Protein Assay (Thermo-
Fischer Scientiﬁc). Protein from each cell-lysate was
separated by SDS–PAGE, followed by electrotransfer into
a nitrocellulose membrane. Proteins of interest were
visualised and quantiﬁed after primary antibody incuba-
tion using Pierce™ ECL Western Blotting Substrate
(ThermoFisher Scientiﬁc) and ChemiDoc Imaging System
(Bio-Rad). Mean band intensity was calculated using
Image Lab software. Primary antibodies were as follows:
H3K4me3 (Millipore; 04-745), H3K27me3 (Millipore; 07-
449), H3K27ac (Millipore; 07-360) and EZH2 (Diagenode;
pAb-039-050) were used as primary antibodies; anti-
β-actin (Sigma; A1978) and anti-Total H3 (Abcam;
ab1791) were used as loading controls.
Chromatin immunoprecipitation (ChIP) and ChIP-seq
ChIP was performed as previously described50,51 using
dynabeads protein G (Invitrogen) with 2.4 mg per 10 ml
beads with 1 μg anti-H3K4me3 (Millipore; 04-745), anti-
H3K27ac (Millipore; 07-360), anti-H3K27me3 (Millipore;
07-449) and anti-EZH2 (Diagenode; pAb-039-050) anti-
bodies. See Supplementary Table 3 for primer sequences.
For sequencing (ChIP-seq), libraries were prepared
using NEBNext® Ultra™ II DNA Library Prep Kit (New
England Biosciences). See Supplementary Methods for
sequencing run details and Supplementary 4 for QC of
these libraries.
Bioinformatics analysis
See Supplementary Methods for further details.
Sequence data from this study have been submitted to
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) under
accession number E-MTAB-6410.
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